Biopharmaceutical company Merck (NYSE: MRK), known as MSD outside the US and Canada, on Wednesday announced positive results from two Phase 3 trials evaluating its investigational HIV treatment, doravirine/islatravir (DOR/ISL).
The once-daily, oral, two-drug regimen demonstrated non-inferiority to existing antiretroviral therapies in maintaining viral suppression at Week 48.
Data from trials MK-8591A-052 and MK-8591A-051 showed that DOR/ISL maintained HIV-1 viral suppression in adults previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or other baseline antiretroviral therapy (bART). The regimen also exhibited a safety profile comparable to the standard treatments, with no cases of treatment-emergent resistance to DOR or ISL observed.
Merck plans to submit applications for regulatory approval by mid-2025. The findings were presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Centivax partners with Emery Pharma on universal flu vaccine
Hansa Biopharma completes enrolment for 20-HMedIdeS-19 PAES study
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy
Gan & Lee doses first participant in Phase 2 clinical trial of bofanglutide injection
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Polarean expands Xenon MRI imaging for pharma-sponsored research
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
Arrowhead Pharmaceuticals reports positive topline results for ARO-C3 in IgA nephropathy trial